Health & Fitness
Thu, December 1, 2011
PRINCETON, N.J.--([ BUSINESS WIRE ])--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care announced today that the Company will be presenting at two upcoming conferences:
The Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Conference in San Francisco on December 6, 2011 at 3:40 p.m. Pacific time. The conference is being held at the St. Regis San Francisco. To assess the live webcast of this presentation, which is being run as a continuous stream, please visit [ http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=3742420 ].
The Oppenheimer & Co. 22nd Annual Healthcare Conference in New York City on December 13th, 2011 at 2:45 p.m. Eastern time. The conference is being held at the Waldorf=Astoria hotel. To access the live webcast of this presentation please visit [ http://www.veracast.com/webcasts/opco/healthcare2011/44119337.cfm ].
Both presentations will be archived after the live event and available for 90 days following the conference. In addition, it will be available for 90 days on the Investor Relations section of the Derma Sciencesa website at [ www.dermasciences.com ].
About Derma Sciences, Inc.
Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed the treatment phase of a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, a novel pharmaceutical drug under development for accelerated wound healing and scar reduction. Its MEDIHONEY product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB for better management of wound exudate, and BIOGUARD for infection prevention.
For more information please visit [ www.dermasciences.com ].
